Rabeprazole

Rabeprazole (CAS 117976-89-3), also referenced in development literature as E-3810 and LY307640, is a proton pump inhibitor (PPI) active pharmaceutical ingredient used in the treatment of acid-related gastrointestinal disorders.

Where is Rabeprazole used?

• Finished dosage form manufacturers and generic drug developers: target API
• Delayed-release oral solid dosage forms: active ingredient
• Enteric-coated tablets and capsules for gastroesophageal reflux disease, peptic ulcers, and Zollinger-Ellison syndrome
• Generic pharmaceutical manufacturers produce bioequivalent formulations for regulated markets in the US, EU, and Asia-Pacific
• CDMOs procure it for combination therapies, including H. pylori eradication regimens paired with antibiotics
• Formulators working on pediatric or modified-release formats may source it as an intermediate for specialized dosage development.

Good to know: The sodium salt form (Rabeprazole Sodium) is the predominant commercial grade. Material is available to USP, BP, and Ph. Eur. pharmacopoeial standards, supporting regulatory submissions across major markets.

Commercial specifications

• Sodium salt form (Rabeprazole Sodium) is the predominant commercial grade
• USP, BP, and Ph. Eur. pharmacopoeial standards
• Packaging under inert atmosphere or moisture-controlled conditions to maintain API integrity during storage and transit